Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle
Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.
/ 3 items
#VALN↓
Pfizer and Valneva Lyme Vaccine Shows Over 70% Efficacy in Phase 3 Trial — But Misses Main Goal
Pfizer and Valneva reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions.
Valneva Withdraws Chikungunya Vaccine from U.S. Market
Valneva voluntarily withdraws its IXCHIQ chikungunya vaccine from the U.S. following FDA suspension and a serious adverse event report, while maintaining licenses in Europe, Canada, UK, and Brazil.